The Type A meeting outcome is the next catalyst; a clear resubmission path could stabilize the stock, while further delays or additional data requirements would pressure the cash runway and likely force dilutive financing. Monitor for meeting minutes and any capital raise announcements.
Price Chart
Executive Summary
Grace Therapeutics reported fiscal year 2026 results with a reduced net loss of $7.8M ($0.47/share) vs $9.6M ($0.79/share) in FY2025, driven by lower R&D spend after the Phase 3 trial close-out. The key event is the April 2026 FDA Complete Response Letter (CRL) for GTx-104, with a Type A meeting scheduled to clarify the resubmission path. The CRL is a major regulatory setback for this pre-revenue biotech, and the stock's $30M market cap reflects high uncertainty around approval and cash runway.
Key Facts
- FDA issued a Complete Response Letter (CRL) for GTx-104 NDA on April 23, 2026, citing CMC and non-clinical items; no clinical deficiencies.
- Type A meeting with FDA scheduled to clarify path to NDA resubmission.
- FY2026 net loss improved to $7.8M ($0.47/share) from $9.6M ($0.79/share) in FY2025.
- Cash and equivalents $17.0M as of March 31, 2026, expected to fund operations for at least 12 months.
- No revenue; company is pre-commercial with GTx-104 as sole pipeline asset.
Financial Impact
CRL delays potential approval and revenue generation; $17M cash runway provides ~12 months of operations but may require additional financing if resubmission timeline extends.
Risk Factors
- FDA may require additional clinical or CMC data, extending timeline and increasing costs.
- Cash runway may be insufficient if resubmission process takes longer than expected, leading to dilutive equity offering.
- GTx-104 is the only pipeline asset; any regulatory failure would render the company valueless.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3314120 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 6w ago | Insider Cluster | $2.26 $2.22 | ▼ −1.77% | ▼ −2.62% | $1.93 (−14.60%) |
Aug 13, 2026 10w ago | 8-K | $2.07 $2.16 | ▲ +4.35% | ▲ +4.55% | $1.93 (−6.76%) |
Aug 13, 2026 10w ago | Press Release | $2.07 $2.16 | ▲ +4.35% | ▲ +4.55% | $1.93 (−6.76%) |
Aug 4, 2026 11w ago | Press Release | $2.14 $2.12 | ▼ −0.93% | ▼ −0.77% | $1.93 (−9.81%) |
Jul 28, 2026 12w ago | 8-K | $2.25 $2.08 | ▼ −7.56% | ▼ −6.02% | $1.93 (−14.22%) |
Jun 18, 2026 18w ago | 8-K | $2.38 $2.26 | ▼ −5.04% | ▼ −4.73% | $1.93 (−18.91%) |
Jun 18, 2026 18w ago | 8-K | $2.38 $2.26 | ▲ +5.04% | ▲ +4.73% | $1.93 (+18.91%) |
Jun 18, 2026 18w ago | Press Release | $2.38 $2.26 | ▲ +5.04% | ▲ +4.73% | $1.93 (+18.91%) |
Jun 5, 2026 20w ago | 8-K | $2.30 $2.33 | ▲ +1.30% | ▲ +1.60% | $1.93 (−16.09%) |
Apr 27, 2026 26w ago | 8-K | $2.16 $2.10 | ▲ +2.78% | ▲ +2.29% | $1.93 (+10.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers